Download Free Sample Report

The global Adalimumab Injection market was valued at US$ 1872.7 million in 2023 and is projected to reach US$ 2698.8 million by 2030, at a CAGR of 5.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
40mg/0.8ml Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Adalimumab Injection include AbbVie, Amgen, Sandoz, Fresenius Kabi, Biogen, Celltrion, Cadila Pharmaceuticals, Bio-Thera Solutions, Ltd. and Hisun Biopharmaceutical, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Adalimumab Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab Injection. This report contains market size and forecasts of Adalimumab Injection in global, including the following market information:

• Global Adalimumab Injection Market Revenue, 2019-2024, 2025-2030, ($ millions)
• Global Adalimumab Injection Market Sales, 2019-2024, 2025-2030, (K Units)
• Global top five Adalimumab Injection companies in 2023 (%)

We surveyed the Adalimumab Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adalimumab Injection Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Adalimumab Injection Market Segment Percentages, by Type, 2023 (%)

• 40mg/0.8ml
• 20mg/0.4ml

Global Adalimumab Injection Market, by Application, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Adalimumab Injection Market Segment Percentages, by Application, 2023 (%)

• Hospitals
• Clinics
• Others

Global Adalimumab Injection Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Adalimumab Injection Market Segment Percentages, By Region and Country, 2023 (%)

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
• The Middle East and Africa (Middle East, Africa)
• South and Central America (Brazil, Argentina, Rest of SCA)

Competitor Analysis
The report also provides analysis of leading market participants including:

• Key companies Adalimumab Injection revenues in global market, 2019-2024 (Estimated), ($ millions)
• Key companies Adalimumab Injection revenues share in global market, 2023 (%)
• Key companies Adalimumab Injection sales in global market, 2019-2024 (Estimated), (K Units)
• Key companies Adalimumab Injection sales share in global market, 2023 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AbbVie
• Amgen
• Sandoz
• Fresenius Kabi
• Biogen
• Celltrion
• Cadila Pharmaceuticals
• Bio-Thera Solutions, Ltd.
• Hisun Biopharmaceutical
• Innovent Biologics
• Mylan
• Zydus Group
• Boehringer Ingelheim
• Jiangsu Chia Tai-Tianqing Pharmaceutical
• Shanghai Henlius Biotech

Outline of Major Chapters:
Chapter 1: Introduces the definition of Adalimumab Injection, market overview.
Chapter 2: Global Adalimumab Injection market size in revenue and volume.
Chapter 3: Detailed analysis of Adalimumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Adalimumab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Adalimumab Injection capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.